



News Release

July 3, 2024

FOR IMMEDIATE RELEASE

Biocure Technology Inc (“CURE”) Announces Termination of Transaction with Atriva Therapeutics

VANCOUVER, British Columbia, July 3, 2024 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE:CURE) announces, further to its press releases dated September 18, 2023 and March 26, 2024, the letter agreement (the “Agreement”) with Atriva Therapeutics GmbH (“Atriva”), pursuant to which the Company would have acquired all of the outstanding securities of Atriva (the “Transaction”), has been mutually terminated due to passage of time without completion of the Transaction.

There was no penalty or termination fee payable by either the Company or Atriva in connection with the termination of the Agreement. Trading in the common shares of the Company was halted on September 18, 2023, upon announcement of the Transaction in accordance with the policies of the Canadian Stock Exchange (“CSE”). As the Transaction will not proceed, trading of the Company’s shares is expected to resume on the CSE once approved by the CSE.

ON BEHALF OF THE BOARD OF DIRECTORS

/S/ “SIMON CHENG”
CEO and Director

For further information, please contact:

Biocure Technology Inc. Telephone: 604-609-7146, or info@biocuretech.com

Certain statements in this news release, which are not historical in nature, constitute “forward looking statements” within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company’s proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management’s current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the “CSE”) nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.